Navigation Links
Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
Date:5/31/2013

HAYWARD, Calif., May 31, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex , President and Chief Executive Officer, and Dr. Colin Hislop , Senior Vice President and Chief Medical Officer, will present a corporate update at the 2013 Annual Jefferies Global Healthcare Conference.

Anthera will present on at 1:30PM ET, June 6th in Ballroom 1 of the Grand Hyatt Hotel in New York City.

About Blisibimod and PEARL-SC

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens.  However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and rheumatoid arthritis.

In April 2012, Anthera completed the PEARL-SC Phase 2b clinical study to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus. In June and July of 2012 Anthera announced results fro
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
2. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
3. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
4. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
7. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
8. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
9. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
10. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
(Date:12/15/2014)... BERGEN, Norway , December 15, 2014 ... developing innovative drugs for aggressive drug resistant cancers, today ... million) in a private placing from new and existing ... the financing to support the development of its pipeline ... development program for its lead drug candidate, BGB324, a ...
(Date:12/15/2014)... 2014 Investor-Edge has initiated coverage on ... Eli Lilly and Company (NYSE: LLY ), Nektar ... SNY ), and Novartis AG (NYSE: NVS ). ... http://investor-edge.com/register . On Friday, December 12, 2014, ... Jones Industrial Average lost 1.79%, to finish the day at ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5
... Sheets: GOHE),announces the initiation of further clinical trials ... expected patient clinical group of 200,patients in 6 ... the Sports,Medicine Institute at The Methodist Hospital in ... Dr. Bryan was formerly the Team,Physician for the ...
... Dosing Regimen, SEATTLE, May 7 Trubion ... its partner, Wyeth Pharmaceuticals, a,division of Wyeth (NYSE: ... the next,Phase 2b clinical trial of TRU-015 in ... Wyeth Pharmaceuticals is developing,TRU-015, SBI-087 and other CD20-directed ...
Cached Medicine Technology:Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4
(Date:12/17/2014)... 2014 A group of 127 scientists sent ... in reaction to a recent statement by the center that ... and derogated the efficacy of all brain exercises. , Signatories ... parts of the center’s statement critical of brain exercise companies ... also overstated its case, in a document it had entitled ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Poor students get more fruits and ... study finds. But, the opposite is true for students ... and vegetables at school may give a healthy boost to ... matter what the family income level, students all ate a ... found. The study was published recently in the journal ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... work commitment is a big reason why, new research suggests. ... Mathias Basner, an assistant professor of sleep and chronobiology in ... A time-use survey of nearly 125,000 Americans, ages 15 ... exchanged for sleep. Short sleepers -- those who slept six ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), ... a new study providing evidence on the impact of ... children. , Sufficient enough evidence already exists showing a ... juice drinks, with the onset of tooth decay. One ... listed as 100% fruit juice, meaning it is completely ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... Heart Association Meeting Report:, COLORADO SPRINGS, Colo., ... improve their quality of life by exercising,as little ... reported at the American,Heart Association,s Conference on Nutrition, ... Exercise in postmenopausal Women (DREW) study,first reported in ...
... release is available in French and German ... of basic biological questions ranging from the role of lipids ... The 79 research groups include 39 from the two federal ... the Swiss universities, one group is part of the Swiss ...
... children prone to cancers; those not-yet-born a bit luckier, new ... Japanese survivors of the atomic bombs dropped by the U.S. ... young children appear to face a greater risk of developing ... new research suggests. , To date, the risk posed by ...
... the laboratory suggests that a new compound can point the ... latent form of the bacterium, says a team led by ... A drug with such properties could also be useful in ... treatment period. The discovery also points to new ways of ...
... Health Care, INDIANAPOLIS, March 14 Consumers ... of a ban on,physician-owned hospitals. The ban, found ... solidly passing through the House. President Robert,Johnson encourages ... support,the passage of HR 1424 and effectively ban ...
... Legislation Would Create and Fund Innovative National System ... Health,Research, WASHINGTON, March 14 In an ... research institutions,have come together to support an innovative ... support for pediatric research. This situation has,been described ...
Cached Medicine News:Health News:Overweight, Obese Women Improve Quality of Life With 10 to 30 Minutes of Exercise 2Health News:Overweight, Obese Women Improve Quality of Life With 10 to 30 Minutes of Exercise 3Health News:Overweight, Obese Women Improve Quality of Life With 10 to 30 Minutes of Exercise 4Health News:Swiss Systems Biology Initiative announces Flagship Projects 2Health News:Fallout From Atomic Bombs Still Causing Health Problems 2Health News:Fallout From Atomic Bombs Still Causing Health Problems 3Health News:New chemical can kill latent tuberculosis bacteria 2Health News:New chemical can kill latent tuberculosis bacteria 3Health News:Consumer Organization Calls for End to Physician Self-Referral 2Health News:America's Top Pediatric Medical Institutions Unite to Drive Increased Federal Investment in Pediatric Research 2Health News:America's Top Pediatric Medical Institutions Unite to Drive Increased Federal Investment in Pediatric Research 3
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches....
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: